Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | APLNR | P35414 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495349 | 0.92 | TRPV1 (0.45) | WNT3ACNR1GUSBROCK2HPGDS | |
| SCHEMBL16495979 | 0.82 | HPGDS (0.52) | WNT3AROCK2HPGDSALDH1A1MEN1 | |
| SCHEMBL16496345 | 0.80 | HPGDS (0.46) | WNT3AHPGDSALDH1A1MEN1KMT2A | |
| SCHEMBL16495435 | 0.79 | HPGDS (0.56) | HPGDSMAPT | |
| SCHEMBL16496094 | 0.78 | ROCK2 (0.58) | WNT3AROCK2HPGDSROCK1 | |
| SCHEMBL19984789 | 0.78 | APLNR (0.54) | GUSBAPLNRALDH1A1MEN1KMT2A | |
| SCHEMBL19984976 | 0.77 | APLNR (0.54) | ROCK2APLNRKMT2AROCK1MAPT | |
| SCHEMBL16496174 | 0.77 | HPGDS (0.48) | HPGDSALDH1A1KMT2AMAPTHDAC1 | |
| SCHEMBL16495686 | 0.75 | HPGDS (0.58) | HPGDSKMT2AMAPTKDM1AHDAC1 | |
| SCHEMBL16495733 | 0.75 | HPGDS (0.46) | WNT3AHPGDSALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | WNT3A 3244/4885CNR1 500/4885GUSB 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.